New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 4, 2014
09:56 EDTTKMRTekmira rallies sharply, levels to watch
Shares were last up 10.8% to $15.80. At that price resistance is at $16.87, the session high. Support is at $15.28.
News For TKMR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 22, 2014
09:03 EDTTKMRTekmira announces agreement to provide TKM-Ebola-Guinea for clinical studies
Tekmira Pharmaceuticals announced that the company has entered into a Manufacturing and Clinical Trial Agreement with the University of Oxford to provide the new TKM-Ebola-Guinea therapeutic product for clinical studies in West Africa. The studies are expected to commence early next year, subject to finalization of a suitable clinical protocol. The University of Oxford is the representative of the International Severe Acute Respiratory and Emerging Infection Consortium, or ISARIC. ISARIC will conduct clinical studies of TKM-Ebola-Guinea in Ebola virus infected patients, with funding provided by the Wellcome Trust. GMP manufacture of TKM-Ebola-Guinea is now complete and 100 treatment courses are available for the study.
08:48 EDTTKMRTekmira receives clearance to conduct Phase I clinical study with TKM-HBV
Tekmira Pharmaceuticals announced that it has received a No Objection Letter from Health Canada regarding its Clinical Trial Application, allowing the Company to proceed with a Phase I clinical trial with TKM-HBV, a therapeutic agent designed to treat patients chronically infected with hepatitis B virus, or HBV. The company expects to commence a single ascending dose Phase I trial with TKM-HBV in healthy human volunteers in 1Q15, and progress to chronically infected patients in a multi-dosing regimen in the second half of 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use